Search details
1.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38634928
2.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37248424
3.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37676282
4.
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
J Transl Med
; 17(1): 296, 2019 08 29.
Article
in English
| MEDLINE | ID: mdl-31464635
5.
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Future Oncol
; 14(26): 2691-2699, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30207488
6.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Eur Urol Oncol
; 7(1): 102-111, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37481365
7.
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Cancer Treat Rev
; 115: 102530, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36898352
8.
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Cancers (Basel)
; 15(23)2023 Dec 04.
Article
in English
| MEDLINE | ID: mdl-38067406
9.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Tumori
; 109(1): 129-137, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36447337
10.
Exploring the Cardiotoxicity Spectrum of Anti-Cancer Treatments: Definition, Classification, and Diagnostic Pathways.
J Clin Med
; 12(4)2023 Feb 17.
Article
in English
| MEDLINE | ID: mdl-36836147
11.
Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment.
J Clin Med
; 12(6)2023 Mar 08.
Article
in English
| MEDLINE | ID: mdl-36983126
12.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Minerva Urol Nephrol
; 75(4): 460-470, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37530662
13.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Target Oncol
; 18(4): 559-570, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-37369815
14.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Clin Genitourin Cancer
; 21(5): e309-e319.e1, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37062658
15.
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Clin Genitourin Cancer
; 20(5): 498.e1-498.e9, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35768316
16.
What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations.
Cancer Manag Res
; 13: 5203-5210, 2021.
Article
in English
| MEDLINE | ID: mdl-34234563
17.
Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study.
Oncotarget
; 12(3): 221-229, 2021 Feb 02.
Article
in English
| MEDLINE | ID: mdl-33613849
18.
Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.
World J Surg Oncol
; 8: 8, 2010 Feb 05.
Article
in English
| MEDLINE | ID: mdl-20137082
19.
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
Clin Genitourin Cancer
; 18(6): 477-488, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32732112
20.
Targeted therapy in the treatment of metastatic renal cell cancer.
Oncology
; 77 Suppl 1: 122-31, 2009.
Article
in English
| MEDLINE | ID: mdl-20130440